Fresenius Medical Care AG
XMUN:FME

Watchlist Manager
Fresenius Medical Care AG Logo
Fresenius Medical Care AG
XMUN:FME
Watchlist
Price: 42.4 EUR 2.66% Market Closed
Market Cap: 24.9B EUR
Have any thoughts about
Fresenius Medical Care AG?
Write Note

Gross Margin
Fresenius Medical Care AG

25.3%
Current
27%
Average
47.2%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
25.3%
=
Gross Profit
4.9B
/
Revenue
19.4B

Gross Margin Across Competitors

Country DE
Market Cap 24.9B EUR
Gross Margin
25%
Country US
Market Cap 91.8B USD
Gross Margin
11%
Country US
Market Cap 87.7B EUR
Gross Margin
11%
Country US
Market Cap 73B USD
Gross Margin
14%
Country US
Market Cap 20.1B USD
Gross Margin
28%
Country DE
Market Cap 18.8B EUR
Gross Margin
24%
Country US
Market Cap 18.3B USD
Gross Margin
33%
Country US
Market Cap 13.7B USD
Gross Margin
33%
Country DE
Market Cap 12.4B EUR
Gross Margin
25%
Country AU
Market Cap 13.4B AUD
Gross Margin
84%
Country US
Market Cap 8.6B USD
Gross Margin
36%
No Stocks Found

Fresenius Medical Care AG
Glance View

Market Cap
24.9B EUR
Industry
Health Care

Fresenius Medical Care AG is a global leader in providing products and services for individuals undergoing dialysis as a result of chronic kidney failure. Founded in 1996 and headquartered in Bad Homburg, Germany, the company specializes in the development and manufacture of high-quality dialysis equipment and supplies, including dialysis machines and filters. With a network that spans over 150 countries, Fresenius operates numerous dialysis clinics, delivering essential care to a large and growing patient population. Its commitment to innovation and quality care positions it well within the healthcare sector, making it a compelling option for investors seeking exposure in the medical technology domain. As the prevalence of kidney disease rises, driven by factors such as aging populations and increasing diabetes cases, Fresenius Medical Care is poised to capitalize on this expanding marketplace. The company's robust pipeline of therapeutic solutions and its focus on integrating healthcare technologies demonstrate a proactive approach to enhancing patient outcomes. Additionally, Fresenius benefits from a diversified business model that includes both product manufacturing and direct patient care services, which provides resilience against market fluctuations. Investors looking for a company with a strong balance sheet, consistent revenue growth, and a mission-driven approach to healthcare will find Fresenius Medical Care AG to be an attractive choice in their portfolio.

FME Intrinsic Value
49.35 EUR
Undervaluation 14%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
25.3%
=
Gross Profit
4.9B
/
Revenue
19.4B
What is the Gross Margin of Fresenius Medical Care AG?

Based on Fresenius Medical Care AG's most recent financial statements, the company has Gross Margin of 25.3%.